BTAI · Insider Trading
BioXcel Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by BTAI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-14 | Susan E. Atkins | Director | A | +17,000 deriv. | — |
| 2026-06-17 | Javier Rodriguez | See Remarks | M | +35 | — |
| 2026-06-17 | Richard I Steinhart | Chief Financial Officer | M | +35 | — |
| 2026-06-17 | Vimal Mehta | CEO and President | M | +219 | — |
| 2026-06-17 | Frank Yocca | Chief Scientific Officer | M | +35 | — |
| 2026-05-22 | Frank Yocca | Chief Scientific Officer | MIXED | +10,655 | −$7.43K |
| 2026-05-22 | Vimal Mehta | CEO and President | MIXED | +30,339 | −$21.11K |
| 2026-05-22 | Javier Rodriguez | See Remarks | MIXED | +10,940 | −$7.11K |
| 2026-05-22 | Richard I Steinhart | Chief Financial Officer | MIXED | +10,655 | −$7.43K |
| 2026-05-07 | Vimal Mehta | CEO and President | M | +18,000 | — |
| 2026-05-07 | Javier Rodriguez | See Remarks | M | +9,000 | — |
| 2026-05-07 | Frank Yocca | Chief Scientific Officer | M | +9,000 | — |
| 2026-05-07 | Richard I Steinhart | Chief Financial Officer | M | +9,000 | — |
| 2026-03-16 | Richard I Steinhart | Chief Financial Officer | M | +68 | — |
| 2026-03-16 | Javier Rodriguez | See Remarks | M | +68 | — |
| 2026-03-16 | Vimal Mehta | CEO and President | M | +383 | — |
| 2026-03-16 | Frank Yocca | Chief Scientific Officer | M | +68 | — |
| 2026-01-12 | Peter Mueller | Director | A | +17,000 deriv. | — |
| 2026-01-12 | Michael Patrick Miller | Director | A | +17,000 deriv. | — |
| 2026-01-12 | Rajiv Patni | Director | A | +17,000 deriv. | — |
| 2026-01-12 | Michal Votruba | Director | A | +17,000 deriv. | — |
| 2026-01-12 | June Bray | Director | A | +17,000 deriv. | — |
| 2026-01-12 | Sandeep Laumas | Director | A | +17,000 deriv. | — |
| 2026-01-12 | David J. Mack | Director | A | +17,000 deriv. | — |
| 2026-01-05 | Frank Yocca | Chief Scientific Officer | A | +70,000 deriv. | — |
| 2026-01-05 | Vimal Mehta | CEO and President | A | +199,032 deriv. | — |
| 2026-01-05 | Richard I Steinhart | Chief Financial Officer | A | +70,000 deriv. | — |
| 2026-01-05 | Javier Rodriguez | See Remarks | A | +70,000 deriv. | — |
| 2025-12-15 | Frank Yocca | Chief Scientific Officer | M | +68 | — |
| 2025-12-15 | Richard I Steinhart | Chief Financial Officer | M | +68 | — |
| 2025-12-15 | Javier Rodriguez | See Remarks | M | +68 | — |
| 2025-12-15 | Vimal Mehta | CEO and President | M | +383 | — |
| 2025-11-03 | David J. Mack | Director | M | +1,694 | — |
| 2025-10-01 | David J. Mack | Director | M | +1,694 | — |
| 2025-09-16 | Vimal Mehta | CEO and President | M | +382 | — |
| 2025-09-16 | Richard I Steinhart | Chief Financial Officer | M | +68 | — |
| 2025-09-16 | Javier Rodriguez | See Remarks | M | +68 | — |
| 2025-09-16 | Frank Yocca | Chief Scientific Officer | M | +68 | — |
| 2025-09-02 | David J. Mack | Director | M | +1,693 | — |
| 2025-08-05 | Frank Yocca | Chief Scientific Officer | A | +9,000 deriv. | — |
| 2025-08-05 | Richard I Steinhart | Chief Financial Officer | A | +9,000 deriv. | — |
| 2025-08-05 | Javier Rodriguez | See Remarks | A | +9,000 deriv. | — |
| 2025-08-05 | Vimal Mehta | CEO and President | A | +18,000 deriv. | — |
| 2025-07-31 | David J. Mack | Director | M | +1,693 | — |
| 2025-07-22 | Richard I Steinhart | Chief Financial Officer | MIXED | +5,000 | — |
| 2025-07-22 | Javier Rodriguez | See Remarks | MIXED | +5,000 | — |
| 2025-07-22 | Frank Yocca | Chief Scientific Officer | A | +4,375 | — |
| 2025-07-22 | Vimal Mehta | CEO and President | A | +15,625 | — |
| 2025-06-30 | David J. Mack | Director | M | +1,693 | — |
| 2025-06-16 | Frank Yocca | Chief Scientific Officer | M | +68 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Vimal Mehta | CEO and President | 550,160 | $40.66K |
| Javier Rodriguez | See Remarks | 26,838 | $1.98K |
| Richard I Steinhart | Chief Financial Officer | 26,335 | $1.95K |
| Frank Yocca | Chief Scientific Officer | 26,210 | $1.94K |
| David J. Mack | Director | 20,317 | $1.50K |
| Peter Mueller | Director | 13,112 | $969 |
| Matthew T. Wiley | Chief Commercial Officer | 1,580 | $117 |
| Vincent O'Neill | See Remarks | 1,247 | $92 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BTAI quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.